Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy
Posted inCardiology Gastroenterology news

Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy

This study identifies the integrin αV-YAP-CTGF axis in liver sinusoidal endothelial cells as a primary driver of fibrosis and carcinogenesis in congestive hepatopathy. By targeting this mechanosensitive pathway, researchers demonstrated a significant reduction in portal hypertension and liver damage in both murine models and human clinical samples.
From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy
Posted inCardiology Gastroenterology news

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy

Researchers have identified a novel signaling pathway in liver sinusoidal endothelial cells (LSECs) that drives fibrosis and liver cancer in congestive hepatopathy. The study highlights the Integrin αV-YAP-CTGF axis as a critical mechanism and potential therapeutic target for patients with chronic hepatic congestion.
Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort
Posted inGastroenterology news Public Health

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I'm carefully constructing the JSON object, which needs to be a valid, parseable string. I'm focusing on incorporating the main findings of the Phenome India cohort study, adding the detailed clinical context. I'm creating a comprehensive discussion on the implications of MASLD and liver fibrosis. I am making sure the summary is under 50 words, and double-checking that all the fields comply with the expected schema, and I'm prepared to handle the references and image prompt. of MASLD and significant liver fibrosis in high-risk metabolic groups, underscoring a major public health challenge in the region.
SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts
Posted inDiabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑intermediate baseline fibrosis.
Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoints are needed to establish meaningful benefit.